Waters Corporation stock (US9418481035): Q1 2026 results and BD spin-merge integration

Waters Corporation, a leading provider of analytical instruments and software, reported first-quarter 2026 financial results on May 5, 2026, marking a key milestone as the company continues integrating the $17.5 billion spin-merge of Becton Dickinson's Biosciences and Diagnostic Solutions unit. The stock traded at $352.21 USD on May 12, 2026, up 1.19% from the prior trading day, according to market data.

As of: May 13, 2026

By the editorial team – specialized in equity coverage.

Waters Corporation: core business model

Waters Corporation operates as a global provider of analytical laboratory instruments, software, and services. The company serves pharmaceutical, chemical, food and beverage, and environmental industries with mass spectrometry and chromatography platforms. Following the integration of Becton Dickinson's Biosciences and Diagnostic Solutions unit through a $17.5 billion spin-merge transaction, Waters has expanded its portfolio to include diagnostic and life sciences capabilities, positioning itself as a more comprehensive analytical solutions provider for US and international markets.

Q1 2026 results and BD integration milestone

Waters reported first-quarter 2026 financial results on May 5, 2026, according to SEC filings as of May 5, 2026. The company is navigating the integration of the Becton Dickinson spin-merge, which closed as a significant corporate transaction combining Waters' analytical instruments with BD's diagnostic and biosciences operations. This combination creates a larger entity with diversified revenue streams across pharmaceutical development, clinical diagnostics, and life sciences research. The integration represents a strategic shift for Waters, expanding its addressable market beyond traditional analytical chemistry into diagnostic and clinical applications.

Institutional investors have maintained substantial positions in Waters. Madison Asset Management held approximately 293,164 shares worth $111.35 million as of the fourth quarter 2025, making Waters its 19th-largest holding, though the firm trimmed its stake by 4.7% during the period, according to MarketBeat as of May 13, 2026.

Stock performance and market positioning

Waters stock has shown modest gains in recent trading. The stock rose 1.19% on May 12, 2026, closing at $352.21 USD, reflecting steady investor interest despite the complexity of the BD integration. Earlier in 2025, the stock gained 1.50% on July 25, 2025, closing at $302.95 USD, indicating a broader upward trajectory over the past year. For US investors, Waters represents exposure to the analytical instruments and diagnostics sectors, which remain critical to pharmaceutical development, quality control, and clinical testing across North America and globally.

Conclusion

Waters Corporation is executing a significant strategic transformation through the integration of Becton Dickinson's Biosciences and Diagnostic Solutions unit, a $17.5 billion transaction that expands the company's market reach and product portfolio. First-quarter 2026 results, reported on May 5, 2026, reflect the company's progress through this integration period. With stock performance showing modest gains and institutional investors maintaining substantial positions, Waters remains a key player in analytical instruments and diagnostics for US and global markets. The company's ability to successfully integrate the BD operations and realize synergies will be a critical factor for investors monitoring the stock in coming quarters.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.